So I've been looking back at some interesting penny stock plays from a few years ago, and there are definitely some lessons worth revisiting. Back in 2023, there were a few names that caught serious attention in the micro-cap space. Let me break down three that were actually worth watching.

First up was Savara. This biotech company was doing something pretty specific - focused on rare respiratory diseases. What made it interesting wasn't just the science, but the actual progress they were showing. They had just completed enrollment on a Phase 3 trial for this lung disease treatment, hitting 164 patients when they only needed 160. That kind of execution matters. They also raised about 80 million in capital around mid-2023, which gave them real runway. For penny stocks to buy back then, having that kind of financial backing actually meant something. The company was burning cash on R&D like most biotech does, but they had a clear catalyst - trial results were supposed to drop by mid-2024.

Then there was Canaan. Now this one's interesting because it's a hardware play in crypto mining. They were showing solid numbers in Q2 2023 - something like 74 million in quarterly revenue, up from 55 million the quarter before. Their computing power sales jumped 44% quarter-over-quarter. But here's the thing nobody really talks about - they hit regulatory headwinds in Kazakhstan. Mining got licensed, and suddenly they had to pause half their operations in Central Asia. They did secure a partnership with a larger mining operation to help offset that, but it showed how geopolitical and regulatory factors can mess with these penny stocks to buy situations pretty fast.

Ardelyx was the third one. This pharma company actually had revenue coming in - they were selling a product called IBSRELA and pulling in like 18 million per quarter. They had cash on the balance sheet, north of 127 million. Plus they had FDA action pending on a new drug application with an October 2023 target date. In the pharmaceutical space, that's a real catalyst. They also got approval in China moving forward. For penny stocks to buy that actually had commercial traction, this was one of the more compelling ones because they weren't just pure R&D burn.

Looking back now from 2026, the interesting thing about penny stocks to buy in 2023 was that these weren't just lottery tickets. They had specific catalysts - trial readouts, regulatory decisions, revenue growth. That's what separated the noise from actual opportunities. Whether they all panned out is another story, but the framework for evaluating them was solid.